anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Bipolar disorder (BD) is hypothesized to be associated with accelerated biological aging. Telomere length (TL) is a biomarker of aging, and although TL decreases with each cell division, the rate of telomere shortening may be affected by inflammation. We aimed to investigate whether TL is decreased in BD patients and to determine the association between TL and inflammatory markers in such patients.
METHODS: 137 BD patients and 118 healthy controls (HCs) were recruited. Leukocyte TL and plasma levels of cytokines [tumor necrosis factor (TNF)-α, interleukin (IL)-8, IL-6, IL-10, transforming growth factor (TGF)-β1], C-reactive protein (CRP), and brain-derived neurotrophic factor (BDNF) were assessed.
RESULTS: TL did not differ significantly between the BD patients and HCs after adjustment for potential confounding factors (P = 0.79). TL was significantly negatively associated with age (β = -0.007, P < 0.001). In addition, log TNF-α levels were significantly negatively associated with TL (P = 0.009), in both the BD patients (P = 0.02) and HCs (P = 0.05).
CONCLUSION: We found a significant association between TNF-α levels and TL shortening in both BD patients and HCs. However, BD patients did not display increased TL shortening relative to HCs. Studies that involve larger sample sizes and control for the heterogeneity of BD participants will be needed.
For all patients, SOM230 will be given at a starting dose of 60 mg intramuscularly (IM) every 28 days. Dose reduction will be allowed for toxicities which are deemed to be therapy-related. Patients will receive SOM230C (IM) as an outpatient and will be observed for at least 30 minutes for any immediate adverse reactions. Toxicity checks will be done every 2 weeks and laboratory tests every 4 weeks during study therapy). Safety and efficacy will be assessed throughout the treatment period. Toxicities will be graded using the Common Terminology Criteria for Adverse Events, version 4.02.

Therapy will continue for maximum of two years if the patient shows no evidence of disease progression or intolerable toxicity. After completion of all study related therapy patients will complete a 30 day safety follow up visit. Patients who are still benefiting from therapy after two years may continue longer only after discussion between the Principal Investigator (PI) and the drug sponsor.
An apparatus for capturing and storing medical emergency information under the adverse circumstances of the emergency scene, without relying on multiple computers and remote communications for support during use. To accomplish data capture and storage, use of a single ruggedized hand held computer with a graphical user interface employing a touch sensitive display screen, and pen stylus for simplifying documentation of patient demographic, history and medications data, focal patient complaints and problems, vital signs, physical exam findings, medication administration, routes and quantities, motorized vehicle crash history, case disposition, emergency crew, and case review and notes. Collection of focal patient complaints and problems is simplified through a body graphical user interface. Easily accessed reference databases for drugs and protocols support the emergency medical technician. Handwriting recognition, signature capture and numerical data entry enable obtaining of necessary crew and patient signatures and other data, including patient refusal of care. Through the use of a variety of secure communication interfaces, printing or transfer of all data collected is provided to other systems. Full compliance with NHTSA and Utstein minimal data reporting set requirements.
FIELD: medicine. ^ SUBSTANCE: virus-inactivated blood plasma for introduction to the person, in essence, does not contain the agents inactivating viruses, received from donors from whom 10 % or more belong to population of the non-Caucasoid race individuals, thus plasma is received by mixing of blood or blood plasma of A and B groups, it is unessential AB, without adding blood or blood plasmas of the 0 group, and is characterised that it contains: from five to six parts of blood or a blood plasma of the donors having A group of blood, from four to five parts of blood or a blood plasma of the donors having B group of blood, from zero to one part of blood or a blood plasma of the donors having AB group of blood. The pharmaceutical composition for manufacture of a medical product for treatment of deficiencies of factors of coagulation, thrombocytopenic purpura is offered, and for use in a repeated exchange of great volume of plasma. Application a virus-inactivated blood plasma according to the invention for manufacture of a medical product and the way of a virus-inactivated blood plasma manufacture is offered. ^ EFFECT: rising of efficiency of treatment. ^ 10 cl, 2 ex
Evidence indicates that a long period with no symptoms follows infection with HIV. Individuals who are infected with the virus could benefit from therapy with a drug that acts to kill the virus or to stimulate the immune system of the individual or both. The immune system is the means the human body has for fighting infections. Ampligen is a suitable drug for clinical trials against HIV because it has been shown to stimulate the immune system and to inhibit HIV in vitro (test tube) at drug levels that can be achieved without noticeable clinical side effects.

Individuals entered in the study are given ampligen by intravenous infusion once during the first week of the trial and twice a week during the following 8 weeks. The dose each individual receives is determined by the responses of earlier individuals. Each is followed for 12 weeks after the last dose of ampligen is given. Each individual maintains a daily diary listing any symptoms or problems that occur, such as headache, nausea, or change in appetite. Other anti-HIV drugs cannot be taken during the trial, and aspirin or acetaminophen should not be taken for more than 2 hours without consulting the research staff. Blood is drawn at intervals during the trial and follow-up and used to determine the effect of ampligen on the HIV and the immune system as well as to monitor any toxicity and side effects.
A constant subcutaneous insulin aspart infusion is given for 8 hours and upon start a bolus of insulin aspart is given. The bolus in arm C is of a different size then arm B. After the 8 hours of constant infusion follows 3 hours of blood sampling. Period C are optional and it is evaluated if it will be conducted after period A and B has been performed.
The present invention relates to nucleotide sequences of the human Notch and Delta genes, and amino acid sequences of their encoded proteins, as well as fragments thereof containing an antigenic determinant or which are functionally active. The invention is also directed to fragments (termed herein "adhesive fragments"), and the sequences thereof, of the proteins ("toporythmic proteins") encoded by toporythmic genes which mediate homotypic or heterotypic binding to toporythmic proteins. Toporythmic genes, as used herein, refers to the genes Notch, Delta, and Serrate, as well as other members of the Delta/Serrate family which may be identified, e.g., by the methods described herein. Analogs and derivatives of the adhesive fragments which retain-binding activity are also provided. Antibodies to human Notch and to adhesive fragments are additionally provided. In specific embodiments, the adhesive fragment of Notch is that fragment comprising the Notch sequence most homologous to Drosophila Notch EGF-like repeats 11 and 12; the adhesive fragment of Delta mediating heterotypic binding is that fragment comprising the sequence most homologous to Drosophila Delta amino acids 1-230; the adhesive fragment of Delta mediating homotypic binding is that fragment comprising the sequence most homologous to Drosophila Delta amino acids 32-230; and the adhesive fragment of Serrate is that fragment comprising the sequence most homologous to Drosophila Serrate amino acids 85-283.
A dental pulp capping composition can comprise a particulate base material which is non-toxic, and capable of forming a structural capping matrix; and a particulate setting material which is non-toxic, water-soluble, biocompatible, and capable of setting the composition. Optional growth factors can also be introduced into the composition to facilitate dental tissue repair. A complimentary method of restoring damaged tooth features can comprise removing diseased and/or damaged portions of the tooth to expose a prepared tooth region. Water can be added to the dental pulp capping composition to form a workable coherent paste. The workable coherent paste can be introduced into the prepared tooth region. The workable coherent paste can then be shaped within the prepared tooth region and then set to form a rigid biomimetic structure within the prepared tooth region.
BACKGROUND: Micronized purified flavonoid fraction (MPFF) is the most widely prescribed and well-studied venoactive drug available for the treatment of chronic venous disease (CVD). Photoplethysmography (PPG) is used to quantitatively measure venous hemodynamics and provide information about the overall function of the venous system. The aim of this study was to use digital PPG to evaluate the effects of MPFF on venous hemodynamics in patients with CVD.
METHODS: Patients diagnosed with CVD at an outpatient clinic in Bursa, Turkey between February 2018 and July 2020 were assessed for inclusion in this retrospective analysis. Patients who complied with the advised treatment strategy (MPFF 1,000 mg tablets taken orally once daily and compression garments) and attended follow-up visits were included in the analysis. Digital PPG was used to measure venous refilling time (VRT) and venous pumping capacity (VPC) at diagnosis and 6 months of follow-up. The Venous Clinical Severity Score (VCSS) was also obtained at these visits, and patients completed the 20-item Chronic Venous Insufficiency Questionnaire (CIVIQ-20).
RESULTS: In total, 721 patients (mean age 52 years) with C0-C4 CVD were included in the study. PPG showed that VRT and VPC increased significantly from 19.0 sec to 2.0%, respectively, at diagnosis to 27.4 and 4.9%, respectively, at 6 months (both P < 0.05). Mean VCSS improved significantly from 7.9 at diagnosis to 3.1 at 6 months (P < 0.05). Mean CIVIQ-20 score also improved significantly at the 6-month follow-up (20.1 vs 38.6 at diagnosis; P < 0.01).
CONCLUSIONS: In patients with C0-C4 CVD, 6 months of MPFF treatment plus the wearing of compression garments was associated with statistically significant improvements in venous hemodynamic parameters measured by PPG, as well as measures of clinical severity and quality of life.
BACKGROUND: The study aimed to evaluate the efficacy of using near-infrared fluorescent imaging (NIRF) imaging with indocyanine green as an intraoperative tool for achieving complete mediastinal lymph node (LN) resection.
PATIENTS AND METHODS: Between September 2019 and July 2021, patients with potential for esophagectomy due to middle and lower thoracic esophageal cancer were enrolled in this study. All patients were scheduled for NIRF-guided mediastinal lymphadenectomy during esophageal cancer surgery and were appropriately assigned to the NIRF group. Patients who underwent esophagectomy between September 2017 and September 2019 were assigned to the historical control group upon satisfying the inclusion/exclusion criteria. Surgical outcomes and the number of removed LNs were compared between the two groups using 1:1 propensity score matching.
RESULTS: Of 67 eligible patients, 59 patients were included in the NIRF group after postsurgical exclusions. The operative time was significantly shorter in the NIRF group than in the historical control group [180 (140-420) min versus 202 (137-338) min; P < 0.001]. The incidence of postoperative chylothorax and hoarseness were significantly lower in the NIRF group than in the historical control group (0% versus 10.2 %; P = 0.036, 3.4% versus 13.6%; P = 0.047). The number of dissected total LNs, mediastinal LNs, and negative LNs was significantly larger in the NIRF group than in the historical control group. The number of overall metastatic LNs and abdominal LNs was comparable between the two groups.
CONCLUSIONS: NIRF imaging can assist in the thorough and complete mediastinal LNs dissections without increasing complications in patients undergoing esophagectomy.
Experimental: Prolonged Exposure/Pramipexole Prolonged Exposure (PE) Therapy consists of 10 sessions of 90-minute duration, normally conducted once a week. In addition to receiving PE as described above, patients will have Pramipexole treatment.
Esophageal squamous cell carcinoma (ESCC) is one of the most lethal malignancy worldwide. The prognosis is poor with a five-year overall survival rate of 10 to 30 %. Randomized clinical trials have demonstrated that trimodality therapy (TMT), consisted of neoadjuvant concurrent chemoradiation (CCRT) and radical esophagectomy, improves the overall survival for patients with resectable locally advanced disease. Despite of the advancement, the outcome remained unsatisfactory with the median recurrence-free survival around 20 to 25 months and median overall survival around 30 months. It is known that the most important prognostic factor is whether a pathological complete response can be achieved after neoadjuvant CCRT. However, the use of new generation chemotherapeutic agent and epidermal growth factor inhibitors failed to significantly improve prognosis comparing to the standard platinum-based regimen. As a consequence, it is mandatory to develop new pharmacotherapeutic regimen for TMT.

In our previous prospective studies, we found higher levels of serum immune-related biomarkers, VEGF-A, TGF-β1, and soluble PD-L1, before neoadjuvant CCRT were independent associated with inferior overall survival and disease-free survival for locally advanced ESCC treated with neoadjuvant CCRT plus radical esophagectomy. Recent clinical trials have shown the efficacy of anti-PD-1 in recurrent/metastatic ESCC. Besides, preclinical and clinical studies suggested radiotherapy might induce local inflammatory stimulus for the immune modulating drug to boost the integrated response. In addition, preclinical study showed promising anti-cancer efficacy by combination of fractionated radiotherapy, anti-PD-L1 and/or anti-TIGIT immunotherapy. Though several prospective clinical trials have shown the feasibility, safety, and activity of adding anti-TIGIT therapy to anti-PD-L1 drug, and adding anti-PD-L1 therapy to chemotherapy in lung cancer, the safety and activity of combing anti-PD-1/PD-L1 to CCRT or TMT remained largely undetermined. In the present clinical trial, we plan to investigate whether incorporation of tiragolumab (Anti-TIGIT) and atezolizumab (Anti-PD-L1) into standard TMT will be safe while improve the pathological complete response rate. By the present research, we expect to develop a new TMT regimen for this poor prognostic disease.

This study is a single arm open labeled trial to evaluate the safety and pathological response of ESCC patients receiving neoadjuvant Paclitaxel/Cisplatin(TP)-CCRT plus Tiragolumab/Atezolizumab followed by radical esophagectomy. We design to enroll 32 patients to develop the preliminary evidence for incorporating tiragolumab/atezolizumab in locally advanced ESCC.
BACKGROUND: Neglected tropical diseases (NTDs) such as leprosy, lymphatic filariasis (LF), schistosomiasis and onchocerciasis are endemic in several African countries. These diseases can lead to severe pain and permanent disability, which can negatively affect the economic productivity of the affected person(s), and hence resulting into low economic performance at the macrolevel. Nonetheless, empirical evidence of the effects of these NTDs on economic performance at the macrolevel is sparse. This study therefore investigates the effects of the above-mentioned NTDs on economic performance at the macrolevel in Africa.
METHODS: The study employs a panel design with data comprising 24 to 45 African countries depending on the NTD in question, over the period, 2002 to 2019. Gross domestic product (GDP) is used as the proxy for economic performance (Dependent variable) and the prevalence of the above-mentioned NTDs are used as the main independent variables. The random effects (RE), fixed effects (FE) and the instrumental variable fixed effects (IVFE) panel data regressions are used as estimation techniques.
RESULTS: We find that, an increase in the prevalence of the selected NTDs is associated with a fall in economic performance in the selected African countries, irrespective of the estimation technique used. Specifically, using the IVFE regression estimates, we find that a percentage increase in the prevalence of leprosy, LF, schistosomiasis and onchocerciasis is associated with a reduction in economic performance by 0.43%, 0.24%, 0.28% and 0.36% respectively, at either 1% or 5% level of significance.
CONCLUSION: The findings highlight the need to increase attention and bolster integrated efforts or measures towards tackling these diseases in order to curb their deleterious effects on economic performance. Such measures can include effective mass drug administration (MDA), enhancing access to basic drinking water and sanitation among others.
The neuromuscular training program will consist of three 90-minute training sessions per week for 6 weeks. The 3 components of the dynamic neuromuscular training protocol utilized in this study include: (1) balance training and hip/pelvis/trunk strengthening, (2) plyometrics and dynamic movement training, and (3) resistance training. Following the completion of the training program, each subject will be re-evaluated to determine change in total, anterior-posterior, and medial-lateral single-limb stability. Two-way analysis of variance models will be used to determine differences between pre-training and post-training and between limbs.
The objective of the present invention is to provide support such that an amount of activity of a user reaches a target value. An information processing device 100 is provided with an activity amount acquiring unit 111, a target value acquiring unit 113, a comparing unit 114, a proposal determining unit 115, and a proposal output unit 116. The activity amount acquiring unit 111 acquires an amount of activity of a user. The target value acquiring unit 113 acquires a target value of the amount of activity. The comparing unit 114 compares the target value or a value based on the target value with an integrated value of the amount of activity. If the integrated value of the amount of activity is lower than the target value or the value based on the target value, and a predetermined condition is satisfied, the proposal determining unit 115 uses location information to determine a proposal for the user, the proposal including an activity related to a household task. The proposal output unit 116 outputs the proposal.
NEW MATERIAL:A thiadinoimidazole derivative shown by the formula I (A is C, or N; R1 and R2 are H or alkyl, but R1 and R2 are not H simultaneously) and its acid addtion salt. EXAMPLE:3,4-Dihydro-4-n-propyl-2H-(1,3)-thiazino[3,2-a]pyrido[3,2-d]im idazole. USE:A drug for the circulatory system having crown blood vasodilating action, telangiectatic action, and mild hypotensive action. PROCESS:A compound shown by the formula II is reacted with a compound shown by the formula III (X and Y are halogen), to give a compound shown by the formula I. The reaction is carried out in a solvent, e.g., methanol, ethanol, etc. in the presence of a base, e.g., NaOH, KOH, etc.
The quality of care for the chronically ill is to be improved through interprofessional cooperation (IPC). To date, evaluation projects on IPC have mostly focused on the inpatient sector. The aim was to use a multiple case study design to investigate forms of IPC in primary care and to identify facilitating and inhibiting factors. Factors that facilitated the implementation of IPC included having a responsible person employed to provide the service, supportive training, and the introduction of evidence-based interventions. There appeared to be insufficient incentives to implement IPC and the needs of the chronically ill were poorly integrated. More systematic evaluation of IPC initiatives is needed to demonstrate their added value. Greater integration of patient needs is key.
A humidified mixture of gas will be delivered by mask, nasal cannulae, and small room-sized tent. Inspiratory oxygen fraction (FiO2) will be gradually decreased to 11% over a period or five days to obtain a peripheral capillary O2 saturation (SpO2) between 80%-85% (corresponding to 40-55 mmHg of arterial partial oxygen pressure (PaO2)). Healthy volunteers will be monitored and blood and urine will be obtained at 24h and 48 hours after returning to normoxia.
PURPOSE: To provide a method for obtaining freeze-dried product of erythrocyte cell capable of being reformed into the erythrocyte cell by dipping many erythrocytes in a buffer solution containing a polymer such as monosaccharides and polyvinylpyrrolidone, and a polyanion, refrigerating the dipped erythrocytes, and further subliming water therefrom. CONSTITUTION: A medium for freeze drying of erythrocyte cell comprising a buffer solution containing 7.0-37.5% (especially 23%) monosaccharides (e.g. xylose, glucose and ribose) and at least 0.7% polymer having 1K-360K (especially 5K-50K) molecular weight (e.g. polyvinylpyrrolidone and dextran), and at least 0.01% (especially 0.1-1.0%) polyanion (e.g. pyrophosphoric acid, triphosphoric acid and 2,3-diphosphoglyceric acid) is obtained. The objective freeze-dried erythrocyte cells are obtained by dipping the many erythrocyte cells in the medium for freeze drying of the erythrocyte cells and freezing the dipped erythrocyte cells and subliming water therefrom to dry in the method for obtaining freeze-dried product of the erythrocyte cell.  The reforming of the erythrocyte cell is performed by bringing the freeze-dried erythrocyte cells into contact with an aqueous solution containing an amphihilic polymer having 1K-360K molecular weight, and having 20wt.% concentration.
The invention discloses an application of nattokinase in a medicine for treating migraine. The nattokinase is prepared by fermenting nattokinase strains. The nattokinase serving as an active component is applied to the medicine for treating the migraine alone or in combination with other medicines. The nattokinase can obviously improve the phenomena that ears of a rat are red, heads are bent and cage climbing times are obviously increased due to migraine. Moreover, the nattokinase has obvious inhibition effect on platelet aggregation, and the inhibition effect is gradually enhanced along with the increase of the dosage. Therefore, the nattokinase can be used for treating migraine caused by platelet aggregation. In addition, the nattokinase can also obviously reduce the concentration of platelet calcium ions caused by thrombin, because the nattokinase can inhibit platelet aggregation induced by the thrombin, thereby reducing the release of 5-hydroxytryptamine and achieving the effect of relieving migraine. In conclusion, in the embodiment of the invention, the nattokinase has a remarkable migraine treatment effect.